Cargando…

The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature

Sarcoidosis and sarcoid-like reactions (SLR) have been repeatedly reported in patients with melanoma treated with BRAF and MEK inhibitors. In the current study we present three patients that developed SLR under treatment with BRAF and mitogen-activated protein kinase (MEK) inhibitors for melanoma. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anastasopoulou, Amalia, Diamantopoulos, Panagiotis T., Skalioti, Chrysanthi, Liapis, George, Psychogiou, Eleni, Ziogas, Dimitrios C., Gogas, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532252/ https://www.ncbi.nlm.nih.gov/pubmed/34691245 http://dx.doi.org/10.1177/17588359211047349

Ejemplares similares

Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2020)

Challenges in the treatment of melanoma with BRAF and MEK inhibitors in patients with sickle cell disease: case report and review of the literature
por: Diamantopoulos, Panagiotis T, et al.
Publicado: (2023)

Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy
por: Ziogas, Dimitrios C, et al.
Publicado: (2020)

When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report
por: Ziogas, Dimitrios C, et al.
Publicado: (2020)

A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy
por: Papaxoinis, George, et al.
Publicado: (2020)

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
por: Anastasopoulou, Amalia, et al.
Publicado: (2023)

Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
por: Anastasopoulou, Amalia, et al.
Publicado: (2022)

Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Clinicopathologic features and treatment outcomes of patients with fibrillary glomerulonephritis: A case series
por: Marinaki, Smaragdi, et al.
Publicado: (2021)

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations
por: Anastasopoulou, Amalia, et al.
Publicado: (2019)

Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers
por: Ziogas, Dimitrios C., et al.
Publicado: (2022)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Treatment of HIV-Associated Lupus-like Membranous Nephropathy with Tacrolimus: A Case Report and Review of the Literature
por: Kofotolios, Ioannis, et al.
Publicado: (2023)

Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field
por: Stafylidis, Christos, et al.
Publicado: (2022)

Sarcoid-like reactions in patients receiving modern melanoma treatment
por: Dimitriou, Florentia, et al.
Publicado: (2018)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment
por: Fotiou, Despina, et al.
Publicado: (2021)

Sarcoid Here, Sarcoid There, Sarcoid Everywhere
por: Iskander, Peter A, et al.
Publicado: (2023)

Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy
por: Abston, Eric, et al.
Publicado: (2020)

Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma
por: Faut, Marloes, et al.
Publicado: (2018)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis
por: Vallianou, Kalliopi, et al.
Publicado: (2020)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

De Novo Minimal Change Disease following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor
por: Marinaki, Smaragdi, et al.
Publicado: (2021)

Drug-Induced Podocytopathies: Report of Four Cases and Review of the Literature
por: Athanasopoulou, Diamanto, et al.
Publicado: (2023)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

MEK + CDK4 a regimen for non-BRAF V6000 melanoma
por: Sosman, Jeff
Publicado: (2015)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition
por: Morales, Delphine, et al.
Publicado: (2021)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tl9d5a6q2o72ocetue3as82ihl